Overweight and obesity in patients with ulcerative colitis: prevalence and associations
https://doi.org/10.31146/1682-8658-ecg-182-10-33-38
Abstract
The disorder of immunoregulation and activation of the immune response in relation to antigens of the intestinal microfl ora in genetically predisposed individuals under the infl uence of certain environmental factors is currently considered as the main theory of the infl ammatory bowel diseases pathogenesis. The morbidity and prevalence of ulcerative colitis (UC) is increasing simultaneously with the obesity pandemic. In recent years, information has appeared on the epidemiological interaction of predisposing factors for obesity and UC.
Study objective is to assess the prevalence of overweight and obesity in patients with UC in the Western Siberian region before the fi rst symptoms of the disease and during treatment, as well as to assess the body mass index (BMI) in patients with UC depending on gender, lesion length, severity, duration of the disease and biologic therapy.
Materials and methods: a case-control study was conducted with 127 patients having UC and 63 healthy ones, comparable by sex and age. BMI was calculated by the formula: mass (kg)/weight (m²).
Results: overweight and/or obesity were noted before the onset of the fi rst symptoms of the disease in 58% of patients with UC of the Western Siberian region. Moreover, a statistically signifi cant predominance of overweight and obesity was observed in men. Dynamic monitoring of patients with UC revealed a lower BMI in patients with total lesion, severe course of the disease, and also against the background of a long-term disease. Biologic therapy helps to increase the BMI.
About the Authors
G. R. Bikbavova
Federal state budgetary educational institution of higher education “Omsk State Medical University” of the Ministry of Healthcare of Russia
Russian Federation
Russian Federation
Department of Hospital Therapy, Endocrinology, Associate Professor, PhD in Medical sciences
644099, Omsk, Russia, Lenin str., 12
M. A. Livzan
Federal state budgetary educational institution of higher education “Omsk State Medical University” of the Ministry of Healthcare of Russia
Russian Federation
Russian Federation
D. Sci. (Med.), Professor, Rector, Head of the Department of Faculty Therapy, Occupational Diseases
Scopus Author ID: 24341682600
644099, Omsk, Russia, Lenin str., 12
E. A. Shmurygina
Federal state budgetary educational institution of higher education “Omsk State Medical University” of the Ministry of Healthcare of Russia
Russian Federation
Russian Federation
5th year student of the Faculty of Medicine
644099, Omsk, Russia, Lenin str., 12
L. V. Mihaleva
Budgetary health institution of the Omsk region “Regional Clinical Hospital”
Russian Federation
Russian Federation
gastroenterologist
644111, Omsk, Russia, Berezovaya str., 3
References
1. Mendall M., Harpsoe M. C., Kumar D., et al. Relation of body mass index to risk of developing inflammatory bowel disease amongst women in the Danish National Birth Cohort. PLoS ONE. 2018, no.13, Е0190600.
2. Bikbavova G. R ., Livzan M. A., Sovalkin V. I., Turchaninov D. V., Tretyakova T. V., Lopatina O. E., Panova T. Yu. The effect of nutritional factors on the development of ulcerative colitis. Experimental and Clinical Gastroenterology. 2019;(2):24–27. (In Russ.) https://doi.org/10.31146/1682–8658-ecg-162–2–24–27
3. Bikbavova G. R., Livzan M. A., Sovalkin V. I., et al. Modern lifestyle and its impact on the ulcerative colitis incidence. The Russian Archives of Internal Medicine. 2019;9(3):188–193. https://doi.org/10.20514/2226–6704–2019–9–3–188–193
4. GBD2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of infl ammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020, no.5, pp. 17–30.
5. Dedov I. I., Melnichenko G. A., Buttirova S. A. Adipose tissue as an endocrine organ. Obesity and Metabolism. 2006, No. 1, pp. 6–13.
6. Kaplan G. G., Ng S. C. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017, Vol. 152, no. 2, pp. 313–321.
7. Bernstein C. N., Rawsthorne P., Cheang M., Blanchard J. F. A population-based case control study of potential risk factors for IBD. Am. J. Gastroenterol. 2006, no.101, pp. 993–1002.
8. Lynn A. M., Harmsen W. S., Aniwan S., et al. Su1855-prevalence of obesity and influence on phenotype within a population-based cohort of infl ammatory bowel disease patients. Gastroenterology. 2018, no.154, p 608.
9. Garvey W. T., Garber A. J., Mechanick J. I., et al. On behalf of the AACE obesity scientific C. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014, Vol. 20, no. 9, pp. 977–989.
10. Kinlen D., Cody D., O’Shea D. Complications of obesity. QJM. 2018, Vol. 111, no. 7, pp. 437–443.
11. Mensah G. A., Mokdad A. H., Ford E., et al. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin. 2004, no.22, pp. 485–504.
12. Canale M. P., Manca di Villahermosa S., Martino G., et al. Obesity-related metabolic syndrome: mechanisms of sympathetic overactivity. Int J Endocrinol. 2013, 2013:865965.
13. Erlinger S. Gallstones in obesity and weight loss. Eur J Gastroenterol Hepatol. 2000, no.12, pp. 1347–1352.
14. Lauby-Secretan B., Scoccianti C., Loomis D., et al. Body fatness and cancer–viewpoint of the IARC working group. N Engl J Med. 2016, no.375, pp. 794–798.
15. Livzan M. A., Krolevets T. S., Lapteva I. V., Cherkashchenko N. A. Non-alcoholic fatty liver disease in persons with abdominal obesity. Evidence-based gastroenterology. 2014, No. 4, pp. 8–14.
16. Livzan M. A., Akhmedov V. A., Krolevets T. S. et al. Informative value of non-invasive markers of liver fibrosis in patients with non-alcoholic fatty liver disease. Therapeutic archive. 2016, No. 12, pp. 62–68.
17. Seminerio J. L., Koutroubakis I. E., Ramos-Rivers C., et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2015, no.21, pp. 2857–2863.
18. Steed H., Walsh S., Reynolds N. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside, Scotland. Obes. Facts. 2009, no.2, pp. 370–372.
19. Ivashkin V. T., Shelygin Yu.A., Khalif I. L., et al. Clinical guide of russian association of gastroenterology and russian association of coloproctology on diagnostics and treatment of ulcerative colitis. Koloproktologia. 2017, no.1, pp. 6–30.
20. Konovich E. A., Khalif I. L., Shapina M. V. Immunopathogenesis of inflammatory bowel diseases. Russian journal of gastroenterology, hepatology, coloproctology. 2013. No. 4, pp. 69–78.
21. Yatsunenko T., Rey F., Manary M., et al. Human gut microbiome viewed across age and geography. Nature,.2012, no.486, pp. 222–227.
Review
For citations:
Bikbavova G.R., Livzan M.A., Shmurygina E.A., Mihaleva L.V. Overweight and obesity in patients with ulcerative colitis: prevalence and associations. Experimental and Clinical Gastroenterology. 2020;(10):33-38. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-182-10-33-38
Views:
945
Email this article 